Cannabis medicinal na odontologia: uma revisão da literatura

Pierro Neto PA, Pierro LMC, Fernandes ST. Cannabis: 12.000 anos de experiências e preconceitos. BrJP. 2023; 6(Suppl 2): S80-4. [https://doi.org/10.5935/2595-0118.20230055-en]. Kalant H. Medicinal use of cannabis: history and current status. Pain Res Manag. 2001; 6(2): 80-91. [https://doi.org/10.1155/2001/469629]. Carlini EA, Cunha JM. Hypnotic and antiepileptic effects of cannabidiol. J Clin Pharmacol. 1981; 21(8-9 Suppl): 417S-27S. [https://accp1.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/j.1552-4604.1981.tb02622.x] Pablos AB, Martins GA. Cannabinoid Dentistry. J Clin Dent Res. 2024; 21(2): 40-5. [https://www.clinicaldentistry.net/artigo/1057/Est%C3%A9tica-%7C-JCDR-2024-v21n2/15079]. Ware MA, Wang T, Shapiro S, Collet JP; COMPASS study team. Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS). J Pain. 2015; 16(12): 1233-42. [https://doi.org/10.1016/j.jpain.2015.07.014]. Navarrete F, García-Gutiérrez MS, Jurado-Barba R, Rubio G, Gasparyan A, Austrich-Olivares A, et al. Endocannabinoid system components as potential biomarkers in psychiatry. Front Psychiatry. 2020; 11: 315. [https://doi.org/10.3389/fpsyt.2020.00315]. Giorgi V, Marotto D, Batticciotto A, Atzeni F, Bongiovanni S, Sarzi-Puttini P. Cannabis and autoimmunity: possible mechanisms of action. Immunotargets Ther. 2021; 10: 261-71. [https://doi.org/10.2147/ITT.S267905]. Procaccia S, Lewitus GM, Lipson Feder C, Shapira A, Berman P, et al. Cannabis for medical use: versatile plant rather than a single drug. Front Pharmacol. 2022; 13: 894960. [https://doi.org/10.3389/fphar.2022.894960]. Radwan MM, Chandra S, Gul S, ElSohly MA. Cannabinoids, phenolics, terpenes and alkaloids of cannabis. Molecules. 2021; 26(9): 2774. [https://doi.org/10.3390/molecules26092774]. Liktor-Busa E, Keresztes A, LaVigne J, Streicher JM, Largent-Milnes TM. Analgesic potential of terpenes derived from Cannabis sativa. Pharmacol Rev. 2021; 73(4): 98-126. [https://doi.org/10.1124/pharmrev.120.000046]. Brasil. Agência Nacional de Vigilância Sanitária. Resolução da Diretoria Colegiada - RDC nº 660, de 30 de março de 2022. Diário Oficial da União. 31 mar 2022. [https://www.in.gov.br/en/web/dou/-/resolucao-rdc-n-660-de-30-de-marco-de-2022-389908959]. Brasil. Ministério da Saúde. Agência Nacional de Vigilância Sanitária. Resolução da Diretoria Colegiada - RDC nº 1.015, de 2 de fevereiro de 2026. Diário Oficial da União. 2 fev 2026. [https://anvisalegis.datalegis.net/action/ActionDatalegis.php?acao=abrirTextoAto&tipo=RDC&numeroAto=00001015&seqAto=000&valorAno=2026&orgao=RDC/DC/ANVISA/MS&codTipo=&desItem=&desItemFim=&cod_menu=1696&cod_modulo=134&pesquisa=true]. Brasil. Ministério da Saúde. Portaria nº 344, de 12 de maio de 1998. Aprova o Regulamento Técnico sobre substâncias e medicamentos sujeitos a controle especial. Diário Oficial da União. [https://bvsms.saude.gov.br/bvs/saudelegis/svs/1998/prt0344_12_05_1998_rep.html]. Lee CK. Medicinal cannabis law in the USA: history, movements, trends, and countertrends. BrJP. 2023; 6(Suppl 1): S7-11. [https://doi.org/10.5935/2595-0118.20230011-en]. Health Canada. Information for health care professionals: cannabis (marihuana, marijuana) and the cannabinoids [Internet]. Ottawa (ON): Health Canada; 2018 Oct. [https://www.canada.ca/content/dam/hc-sc/documents/services/drugs-medication/cannabis/information-medical-practitioners/information-health-care-professionals-cannabis-cannabinoids-eng.pdf]. European Monitoring Centre for Drugs and Drug Addiction. Cannabis laws in Europe: questions and answers for policymaking. Luxembourg: Publications Office of the European Union; 2023. [https://doi.org/10.2810/151113]. Ransing R, de la Rosa PA, Pereira-Sanchez V, Handuleh JIM, Jerotic S, et al. Current state of cannabis use, policies, and research across sixteen countries: cross-country comparisons and international perspectives. Trends Psychiatry Psychother. 2022; 44(Suppl 1): e20210263. [https://doi.org/10.47626/2237-6089-2021-0263]. Fraga P, Prado M. The construction of a right: the regulation of medicinal cannabis in Argentina and Brazil. Trends Psychiatry Psychother. 2022; 44(Suppl 1): e20210263. [https://www.scielosp.org/pdf/sausoc/2025.v34n1/e240624pt/en]. Hausman-Kedem M, Menascu S, Kramer U. Efficacy of CBD-enriched medical cannabis for treatment of refractory epilepsy in children and adolescents - An observational, longitudinal study. Brain Dev. 2018; 40(7): 544-51. [https://doi.org/10.1016/j.braindev.2018.03.013]. Boyaji S, Merkow J, Elman RNM, Kaye AD, Yong RJ, Urman RD. The role of cannabidiol (CBD) in chronic pain management: an assessment of current evidence. Curr Pain Headache Rep. 2020; 24(4): 4. [https://doi.org/10.1007/s11916-020-0835-4]. Carmona Rendón Y, Garzón HS, Bueno-Silva B, Arce RM, Suárez LJ. Cannabinoids in periodontology: where are we now? Antibiotics. 2023; 12(12): 1687. [https://doi.org/10.3390/antibiotics12121687]. Lowe H, Toyang N, Steele B, Bryant J, Ngwa W, et al. The current and potential application of medicinal cannabis products in dentistry. Dent J. 2021; 9(9): 106. [https://doi.org/10.3390/dj9090106]. Grossman S, Tan H, Gadiwalla Y. Cannabis and orofacial pain: a systematic review. Br J Oral Maxillofac Surg. 2022; 60(5): e677-90. [https://doi.org/10.1016/j.bjoms.2021.06.005]. Oens B. Drug development: the treasure chest. Nature. 2015; 525(7570): S6-8. [https://doi.org/10.1038/525S6a]. Türp JC. Failure in chronic pain therapy across the discipline’s consequences for the management of orofacial pain. Schmerztherapie. 2017; 9(3): 197-208. Santos RMM, Araújo GI, França GNM, Andrade JLSV, Viana LS, et al. Uso terapêutico da cannabis em odontologia no tratamento da dor orofacial: revisão de literatura integrativa. Braz J Implantol Health Sci. 2024; 6(4): 714-25. [https://doi.org/10.36557/2674-8169.2024v6n4p714-725]. Michelotti A, De Wijer A, Steenks M, Farella M. Home-exercise regimes for the management of non-specific temporomandibular disorders. J Oral Rehabil. 2005; 32(11): 779-85. [https://doi.org/10.1111/j.1365-2842.2005.01513.x]. Sihota A, Smith BK, Ahmed SA, Bell A, Blain A, et al. Consensus-based recommendations for titrating cannabinoids and tapering opioids for chronic pain control. Int J Clin Pract. 2021; 75(8): e13871. [https://doi.org/10.1111/ijcp.13871]. Beneng K, Renton T, Yilmaz Z, Yiangou Y, Anand P. Cannabinoid receptor CB1-440 immunoreactive nerve fibres in painful and non-painful human tooth pulp. J Clin Neurosci. 2010; 17(11): 1476-9. [https://doi.org/10.1016/j.jocn.2010.04.005]. McDonough P, McKenna J, McCreary C, Downer E. Neuropathic orofacial pain: cannabinoids as a therapeutic avenue. Int J Biochem Cell Biol. 2014; 55: 72-8. [https://doi.org/10.1016/j.biocel.2014.08.007]. Konermann A, Jäger A, Held S, Brossart P, Schmöle A. In vivo and in vitro identification of endocannabinoid signaling in periodontal tissues and their potential role in local pathophysiology. Cell Mol Neurobiol. 2017; 37(8): 1511-20. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11482071/] Gambino A, Cabras M, Panagiotakos E, et al. Evaluating the suitability and potential efficiency of Cannabis sativa oil for patients with primary burning mouth syndrome: a prospective, open-label, single-arm pilot study. Pain Med. 2020; 21(1): 185-94. [https://doi.org/10.1093/pm/pnaa318] LeResche L. Epidemiology of temporomandibular disorders: implications for the investigation of etiologic factors. Crit Rev Oral Biol Med. 1997; 8(3): 291-305. [https://doi.org/10.1177/10454411970080030401]. Walczynska-Dragon K, Kurek-Górecka A, Niemczyk W, Nowak Z, Baron S, et al. Cannabidiol intervention for muscular tension, pain, and sleep bruxism intensity—A randomized, double-blind clinical trial. J Clin Med. 2024; 13(5): 1417. [https://doi.org/10.3390/jcm13051417]. Grossmann E, Rode SM, Tambeli CH, Tanganeli JPC, Haddad DS. The current state of cannabinoids in orofacial pain. Clinics. 2024; 79: 100528. [https://doi.org/10.1016/j.clinsp.2024.100528]. Tambeli CH, Martins GA, Barbosa SL, Machado TT. Abordagem integrativa do uso terapêutico da cannabis nas dores orofaciais. BrJP. 2023; 6(Suppl 1): S49-53. [https://doi.org/10.5935/2595-0118.20230013-en]. Crippa JA, Guimarães FS, Campos AC, Zuardi AW. Translational investigation of the therapeutic potential of cannabidiol (CBD): toward a new age. Front Immunol. 2018; 9: 2009. [https://pmc.ncbi.nlm.nih.gov/articles/PMC6161644/]. Lobbezoo F, Ahlberg J, Raphael KG, Wetselaar P, Glaros AG, et al. International consensus on the assessment of bruxism: report of a work in progress. J Oral Rehabil. 2018; 45: 837-44. [https://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjoor.12663]. Nitecka-Buchta A, Nowak-Wachol A, Wachol K, Walczyńska-Dragon K, Olczyk P, et al. Myorelaxant effect of transdermal cannabidiol application in patients with TMD: a randomized, double-blind trial. J Clin Med. 2019; 8(11): 1886. [https://doi.org/10.3390/jcm8111886]. Pellegrini G, Carmagnola D, Toma M, Rasperini G, Orioli M, Dellavia C. Involvement of the endocannabinoid system in current and recurrent periodontitis: A human study. J Periodontal Res. 2023; 58(2): 422-32. [https://doi.org/10.1111/jre.13103]. Stahl V, Vasudevan K. Comparison of efficacy of cannabinoids versus commercial oral care products in reducing bacterial content from dental plaque: a preliminary observation. Cureus. 2020; 12(1): e6809. [https://doi.org/10.7759/cureus.6809]. Vasudevan K, Stahl V. Cannabinoids infused mouthwash products are as effective as chlorhexidine on inhibition of total-culturable bacterial content in dental plaque samples. J Cannabis Res. 2020; 2(1): 20. [https://doi.org/10.1186/s42238-020-00027-z]. International Classification of Orofacial Pain – ICOP – Brazilian Portuguese version. Headache Med [Internet]. 2022 Jan. 28; 13(1): 1-2. [https://doi.org/10.48208/HeadacheMed.2022.1]. Pereira SR, Tello Velasquez J, Duggan S, Ivanisevic B, McKenna JP, et al. Recent advances in the understanding of the aetiology and therapeutic strategies in burning mouth syndrome: focus on the actions of cannabinoids. Eur J Neurosci. 2022; 55(4): 1032-50. [https://doi.org/10.1111/ejn.14712]. Yang J, Lin N, Li S, Wang D, Liu Y, et al. Cannabidiol alleviates oral mucositis by inhibiting PI3K/Akt/NF-κB-mediated pyroptosis. Balkan Med J. 2024; 41(4): 286-97. [https://doi.org/10.4274/balkanmedj.galenos.2024.2024-2-66]. Nagamine T. Two-hit theory by estrogen in burning mouth syndrome. J Dent Sci. 2022; 17(4): 1833-4. [https://doi.org/10.1016/j.jds.2022.06.009]. Tan HL, Smith JG, Hoffmann J, Renton T. A systematic review of treatment for patients with burning mouth syndrome. Cephalalgia. 2022; 42(2): 128-61. [https://doi.org/10.1177/03331024211036152]. Umpreecha C, Bhalang K, Charnvanich D, Luckanagul J. Efficacy and safety of topical 0.1% cannabidiol for managing recurrent aphthous ulcers: a randomized controlled trial. BMC Complement Med Ther. 2023; 23(1): 57. [https://doi.org/10.1186/s12906-023-03886-0]. [https://pmc.ncbi.nlm.nih.gov/articles/PMC9940329/pdf/12906_2023_Article_3886.pdf]. Borsani E, Majorana A, Cocchi MA, et al. Epithelial expression of vanilloid and cannabinoid receptors: a potential role in burning mouth syndrome pathogenesis. Histol Histopathol. 2014; 29(4): 523-33. [https://pubmed.ncbi.nlm.nih.gov/24190005/]. Gajofatto A. Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis. Mult Scler Relat Disord. 2016; 8: 64-5. [https://doi.org/10.1016/j.msard.2016.05.004]. Wen SD, Sans-Serramitjana E, Santander JF, Sánchez MR, Salazar-Aguilar P, et al. Effects of natural extracts in the treatment of oral ulcers: a systematic review of evidence from experimental studies in animals. J Clin Exp Dent. 2021; 13(10): e1038-48. [https://doi.org/10.4317/jced.58567]. [https://pmc.ncbi.nlm.nih.gov/articles/PMC8501866/pdf/jced-13-e1038.pdf]. Cooper ZD, Craft RM. Sex-dependent effects of cannabis and cannabinoids: a translational perspective. Neuropsychopharmacology. 2018; 43(1): 34-51. [https://doi.org/10.1038/npp.2017.140]. [https://pmc.ncbi.nlm.nih.gov/articles/PMC5719093/pdf/npp2017140a.pdf]. Cuba LF, Salum FG, Cherubini K, Figueiredo MAZ. Cannabidiol: an alternative therapeutic agent for oral mucositis? J Clin Pharm Ther. 2017; 42(3): 245-50. [https://doi.org/10.1111/jcpt.12504]. Elad S, Yarom N, Zadik Y, Kuten-Shorrer M, Sonis ST. The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies. CA Cancer J Clin. 2022; 72(1): 57-77. [https://doi.org/10.3322/caac.21704]. Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, et al. Cannabidiol adverse effects and toxicity. Curr Neuropharmacol. 2019; 17(10): 974-89. [https://doi.org/10.2174/1570159X17666190603171901]. [https://pmc.ncbi.nlm.nih.gov/articles/PMC7052834/pdf/CN-17-974.pdf]. Garcia JBS, Barbosa Neto JO. Adverse effects of cannabinoid use: what is the safety paradigm? BrJP. 2023; 6(Suppl 1): S38-43. [https://doi.org/10.5935/2595-0118.20230005-en]. Nachnani R, Knehans A, Neighbors JD, Kocis PT, Lee T, et al. Systematic review of drug-drug interactions of delta-9-tetrahydrocannabinol, cannabidiol, and cannabis. Front Pharmacol. 2024; 15: 1282831. [https://doi.org/10.3389/fphar.2024.1282831]. [https://pmc.ncbi.nlm.nih.gov/articles/PMC11167383/pdf/fphar-15-1282831.pdf]. Manikandan P, Nagini S. Cytochrome P450 structure, function and clinical significance: a review. Curr Drug Targets. 2018; 19(1): 38-54. [https://doi.org/10.2174/1389450118666170125144557].